Abstract
Budd-Chiari syndrome is a rather unusual clinical entity; among others, myeloproliferative disorders not infrequently are reported as a cause of this syndrome. In the past prognosis of Budd-Chiari syndrome was usually very poor. However, in recent years treatment with fibrinolytic agents has proved to be often successful in Budd-Chiari syndrome, as well as in other thrombotic disorders. In particular, r-TPA has appeared to be effective, due to its thrombospecificity. Three cases of Budd-Chiari's syndrome associated with myeloproliferative disorders are described, in which r-TPA administration, together with treatment of underlying disease, resulted in a complete recanalization of sovrahepatic veins. r-TPA, due to its thrombospecificity, has been shown to be more effective than other thrombolytic agents; its use is associated with a lower number of hemorrhagic events and it may be repeated in the case of uncompleted response.
Translated title of the contribution | Trombolytic treatment with r-TPA in Budd-Chiari syndrome during myeloproliferative diseases |
---|---|
Original language | Italian |
Pages (from-to) | 241-253 |
Number of pages | 13 |
Journal | Minerva Cardioangiologica |
Volume | 46 |
Issue number | 7-8 |
Publication status | Published - Jul 1998 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine